Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma Progressing After Standard Treatmen : a Randomized, Phase 2, Multi-center Trial [EVERLAST]

NCT07619950 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT07619950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07619950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma Progressing After Standard Treatmen : a Randomized, Phase 2, Multi-center Trial [EVERLAST]
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
November 30, 2028
Enrollment
94 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms of bone and articular cartilage with unspecified anatomical site